Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Drug Interaction Clinical Trial

Official title:

Double-Blind, Randomized, 2-Way Crossover Evaluation of the Impact of a Histamine-H2 Receptor Antagonist (H2RA) on the Pharmacokinetics of Telaglenastat Administered to Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04540965
• Other study ID #: CX-839-015
• Status: Completed
• Phase: Phase 1
• Start date: September 22, 2020
• Est. completion date: December 8, 2020

Study information

• Verified date: March 2021
• Source: Calithera Biosciences, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to formally evaluate the impact of famotidine, an H2R antagonist, on the pharmacokinetics of telaglenastat.

This study will be conducted in up to 22 healthy volunteers, who meet all of the inclusion criteria and none of the exclusion criteria. The study is double-blinded, randomized 2-way crossover in design.

Subjects will receive four 200 mg tablets of telaglenastat either in the presence or absence of 20 mg famotidine (H2R-antagonist) with a 4-day wash-out period in between each regimen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: December 8, 2020
• Est. primary completion date: December 8, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adult male or female, 18-55 years of age, inclusive, at screening.

2. Has not used nicotine-containing products (more than 5 cigarettes/equivalent per week) for at least 3 months prior the first dose and has negative urine cotinine tests at screening, Day 1 and Day 7.

3. Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusively, at screening.

4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the Principal Investigator (PI).

5. For a female of childbearing potential: either be sexually inactive (abstinent - ie, not sexually active with a male partner) for 14 days prior to the first dose and through 14 days following the last dose of any study drug(s) or be using one of the following acceptable birth control methods:

1. Non-hormone releasing intrauterine device in place for at least 3 months prior to the first dose of any study drug with a physical barrier method (eg, condom, diaphragm) from the time of screening through the last dose of any study drug. A progesterone (progestin)-only contraceptive is allowable.

2. A physical barrier method (eg, condom, diaphragm) for at least 14 days prior to the first dose of any study drug and until the last dose of any study drug.

6. In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method until the last dose of any study drug.

7. Females of non-childbearing potential as defined below do not require contraception.

Females of non-childbearing potential:

1. must have undergone one of the following sterilization procedures at least 6 months prior to the first dose of any study drug:

1. hysteroscopic sterilization;

2. bilateral salpingectomy;

1. Women with a tubal ligation less than one year prior to study start must agree to use a barrier method of birth control 3. non-surgical transcervical sterilization (eg, Essure®); 4. hysterectomy; 5. bilateral oophorectomy OR

2. be postmenopausal with amenorrhea for at least 1 year prior to the first telaglenastat dose with follicle-stimulating hormone (FSH) serum levels > 30 IU/mL.

8. A non-vasectomized male subject must agree to use a physical barrier (eg, condom or diaphragm) or abstain from sexual intercourse with female partners during the study until the last dose of any study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non-vasectomized male).

a) Female participants with a vasectomized male partner, or male participants with a female partner of non-childbearing potential do not require contraception.

9. If male, must agree not to donate sperm from dosing until the last dose of any study drug.

10. Alanine and aspartate aminotransferase and bilirubin levels = the upper limit of normal or deemed not clinically significant by the Investigator.

11. Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or is expected to manifest significant emotional problems during the conduct of the study.

2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.

3. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening.

5. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or inactive ingredient(s).

6. History or presence of:

1. liver disease, pancreatic insufficiency or intestinal malabsorption;

2. neuropathy or muscle disorders;

3. seizures;

4. asthma; childhood asthma that has resolved and has not required medical treatment for at least 5 years prior to study start is permitted;

5. fluid retention;

6. cardiovascular disease, cardiac arrhythmias, hypertension, cardiovascular thrombotic events, myocardial infarction, or stroke;

7. ulcer disease or gastrointestinal bleeding;

8. renal papillary necrosis and other renal injury;

9. exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

7. Female subjects who are pregnant or lactating.

8. Positive urine drug or alcohol results at screening or check-in.

9. Positive urine cotinine at screening or check-in.

10. Positive results at screening for HIV types 1 and 2, HBsAg, or hepatitus C virus.

11. Seated blood pressure (taken after 5 minutes in a sitting position) is less than 90/40 mmHg or greater than 140/90 mmHg at screening and not as part of ECG.

12. Seated heart rate (taken after 5 minutes in a sitting position) is lower than 40 bpm or higher than 100 bpm at screening and not as part of ECG.

13. QTcF interval is > 460 msec (males) or > 480 msec (females) or deemed clinically abnormal by the PI at screening.

14. Estimated creatinine clearance < 90 mL/min calculated by the method of Cockcroft and Gault at screening.

15. Unable to refrain from or anticipates the use of:

1. Proton pump inhibitors (PPIs), histamine H2 receptor antagonists (H2RAs), buffering agents (eg, Tums) or any other medication that may have an effect on gastric acid secretion beginning 14 days prior to the first dose of any study drug and throughout the study.

2. Any non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose of any study drug and throughout the study.

3. Any prescription medications (including hormone replacement therapy and lithium) beginning 14 days prior to the first dose of any study drug and throughout the study.

16. Donation of blood or significant blood loss within 56 days prior to the first dose of any study drug.

17. Plasma donation within 14 days prior to the first dose of any study drug.

18. Presence of any medical history or condition that may limit gastric drug absorption (eg, prior gastric surgery, gastric banding, Whipple procedure)

19. Participation in another clinical trial within 28 days prior to the first dose of any study drug. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

Related Conditions & MeSH terms

• Drug Interaction

Intervention

Drug:
• Telaglenastat
Glutaminase inhibitor
• Famotidine
Histamine-H2 Receptor Antagonist
• Placebo for famotidine
Placebo for Histamine-H2 Receptor Antagonist

Locations

Country	Name	City	State
Australia	Nucleus Network Brisbane Clinic (formerly Q-Pharm)	Brisbane	Queensland

Sponsors (2)

Lead Sponsor	Collaborator
Calithera Biosciences, Inc	Novotech (Australia) Pty Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Plasma Concentration (Cmax)	To assess the effect of famotidine on the Cmax of telaglenastat in healthy adult subjects	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat
Primary	Time to peak plasma concentration (Tmax)	To assess the effect of famotidine on the Tmax of telaglenastat in healthy adult subjects	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat
Primary	Area under the concentration-time curve from time = 0 to the last determination (AUClast)	To assess the effect of famotidine on the time to maximum plasma concentration (Tmax) of telaglenastat in healthy adult subjects.	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.
Primary	Area under the concentration-time curve from time = 0 to infinity (AUC0-inf)	To assess the effect of famotidine on the AUC0-inf of telaglenastat in healthy adult subjects	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.
Primary	Half-life	To assess the effect of famotidine on the half-life of telaglenastat in healthy adult subjects	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.
Primary	Elimination rate	To assess the effect of famotidine on the elimination rate of telaglenastat in healthy adult subjects	Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.
Secondary	Incidence of Treatment-Emergent Adverse Events	Assessed by physician reports of any unfavorable and unintended sign, symptom, or disease (new or exacerbated) that is temporally associated with the use of the investigational products.	Safety will be assessed throughout the study, starting from Day 3, prior to receiving the first dose of telaglenastat through to Day 11 when the subjects are released from the clinical site.
Secondary	Incidence of changes in body temperature	Body temperature is measured in degrees Celsius.	Body temperature will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Incidence of changes in respiratory rate.	Respiratory rate is measured in breaths per minute.	Respiratory rate will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Incidence of changes in blood pressure	Blood pressure is measured in mmHg.	Blood pressure will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Incidence of changes in heart rate.	Heart rate is measured in beats per minute.	Heart rate will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Electrocardiograms (ECGs)	Triplicate 12-lead ECGs including P Wave, QRS Complex, and QTcF determination	ECGs will be performed prior to and 4 hours after telaglenastat dosing on Days 3 and 10 and 24 hours after telaglenastat dosing on Days 4 and 11.
Secondary	Hemoglobin assessments	Hemoglobin will be measured in g/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Hematocrit assessments	Hematocrit will be measured in %	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Leukocyte count assessments	Leukocyte count will be measured in 1000 cells/microliter	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Red blood cell count assessments	Red blood cell count will be measured in 1,000,000 cells/microliter	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Platelet count assessments	Platelet count.will be measured in 1000 cells/microliter	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum urea	Serum Urea will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum bilirubin	Serum Bilirubin will be measured in micromoles/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum alkaline phosphatase	Serum alkaline phosphatase will be measured in units/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum Aspartate aminotransferase assessments	Serum Aspartate aminotransferase will be measured in units/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum aspartate aminotransferase	Serum Alanine aminotransferase will be measured in units/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum albumin	Serum Albumin will be measured in g/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum sodium	Serum Sodium will be measured in meq/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum potassium	Serum Potassium will be measured in meq/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum chloride	Serum Chloride will be measured in meq/L	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum glucose	Serum Glucose will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Serum creatinine	Serum Creatinine will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine pH	Urine pH will be measured in units	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Specific gravity	Urine Specific gravity will be measured in g/mL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Protein	Urine Protein will be measured in mg/24 hr	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Glucose	Urine Glucose will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Ketones	Urine Ketones will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Bilirubin	Urine Bilirubin will be measured in mg/dL	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Blood	Urine Blood will be measured in RBC/high powered field	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Nitrite	Urine Nitrite will be measured by dipstick	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Urobilinogen	Urine Urobilinogen will be measured in Ehrlich units	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.
Secondary	Urine Leukocyte esterase.	Urine Leukocyte esterase will be measured in units	Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.